IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v42y2019i12d10.1007_s40264-019-00860-z.html
   My bibliography  Save this article

Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy

Author

Listed:
  • Janet Sultana

    (University of Messina
    Erasmus Medical Centre, Rotterdam)

  • Andrea Fontana

    (Fondazione IRCCS Casa Sollievo della Sofferenza, Unit of Biostatistics)

  • Francesco Giorgianni

    (University of Messina)

  • Silvia Tillati

    (University of Messina)

  • Claudio Cricelli

    (Italian College of General Practitioners)

  • Alessandro Pasqua

    (Italian College of General Practitioners)

  • Elisabetta Patorno

    (Brigham and Women’s Hospital)

  • Clive Ballard

    (University of Exeter Medical School)

  • Miriam Sturkenboom

    (Julius Centre for Global Health, Utrecht University Medical Centre)

  • Gianluca Trifirò

    (University of Messina
    Erasmus Medical Centre, Rotterdam)

Abstract

Introduction Safety warnings relating to antipsychotic-associated stroke among older persons in the UK and Italy were issued. However, the impact of these safety warnings on stroke risk has not been measured to date. Objective The aim of this study was to measure the change in stroke incidence after two safety warnings in both the UK and Italy. Method A cohort study was conducted using electronic medical records representative of the UK (The Health Improvement Network) and Italy (Health Search—IQVIA Health LPD), containing data on 11 million and 1 million patients, respectively. After each drug safety warning, elderly antipsychotic new initiators were propensity-score matched 1:1:1 on antipsychotic initiators before any safety warning. Stroke incidence within 6 months of antipsychotic initiation, using an intention-to-treat approach, was the main outcome. Results In the UK and Italy, 6342 and 7587 elderly antipsychotic initiators were identified, respectively. A 42% stroke incidence reduction was seen in the UK after the first safety warning [42.3 (95% confidence interval (CI) 35.2–50.8) vs. 24.4 [95% CI 19.0–31.2] events per 1000 person-years (PYs)], while there was a 60% stroke incidence reduction after the second warning (16.9 [95% CI 12.2–23.4] events per 1000 PYs) compared to before the first warning. There was no significant reduction in stroke incidence in Italy. Conclusion Antipsychotic safety warnings were followed by a reduction in stroke incidence among older antipsychotic users in the UK, but not Italy.

Suggested Citation

  • Janet Sultana & Andrea Fontana & Francesco Giorgianni & Silvia Tillati & Claudio Cricelli & Alessandro Pasqua & Elisabetta Patorno & Clive Ballard & Miriam Sturkenboom & Gianluca Trifirò, 2019. "Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and," Drug Safety, Springer, vol. 42(12), pages 1471-1485, December.
    • Handle: RePEc:spr:drugsa:v:42:y:2019:i:12:d:10.1007_s40264-019-00860-z
    DOI: 10.1007/s40264-019-00860-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-019-00860-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-019-00860-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Dominic H. P. Balog-Way & Darrick Evensen & Ragnar E. Löfstedt, 2020. "Pharmaceutical Benefit–Risk Perception and Age Differences in the USA and Germany," Drug Safety, Springer, vol. 43(11), pages 1141-1156, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:12:d:10.1007_s40264-019-00860-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.